Loading clinical trials...
Loading clinical trials...
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Conditions
Interventions
Carfilzomib
Lenalidomide
+2 more
Locations
10
United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
May 25, 2018
Primary Completion Date
September 26, 2023
Completion Date
November 15, 2031
Last Updated
December 12, 2023
NCT06383143
NCT02269592
NCT03717844
NCT06365060
NCT06895291
NCT05361694
Lead Sponsor
International Myeloma Foundation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions